30 closest matches · ranked by relevance
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
Cancer · Brain Tumors
Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability
Brain Tumors With Ill-defined Margins
Primary: Extent of Resection — 97.1 percentage of tumor resected
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Brain Neoplasms · Brain Cancer
Primary: 12-month Local Control Rate — 91.4; 95.2 percentage of lesions
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Glioblastoma Multiforme · Brain Metastases
Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Glioblastoma Multiforme · Glioblastoma - Category
Primary: Overall Survival (OS) — 11.73 months
High Grade Glioma
Primary: Response Rate
Brain Cancer
Primary: Time to Cognitive Failure — 7.7; 4.9 months — p=.74
Glioma
Primary: Extent of Resection — 24; 25 participants
Central Nervous System Lymphoma · Malignant Glioma · Metastatic Malignant Neoplasm in the Brain
Primary: Utility of Femumoxytol and Gadolinium Based Contrast Agents for Improved Imaging Biomarkers of Malignant Brain Tumors in a Single Session by Comparing Dynamic Contrast…
Glioblastoma Multiforme
Primary: 6-month Progression-free Survival — 90 months
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
Blood Brain Barrier Defect
Primary: Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion — 19.1; 18.0 percentage of AUC
Adult Anaplastic Oligodendroglioma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…
Brain Cancer
Primary: Number of Participants Who Received PET/CT and MRI Perfusion Studies — 53; 95 Participants
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants
Cancer · Brain Cancer · Meningioma
Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…
Glioma
Primary: Overall Survival at 12 Months — 74; 92 percentage of participants — p=0.03
Brain Metastases
Primary: Maximum Tolerated Dose of Five Fraction Stereotactic Radiotherapy — 35; 30 Gy
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
Brain Tumor
Primary: Number of Patients Assessed for Toxicity According to CTC Version 3.0 — 25 participants
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Recurrent Glioblastoma
Primary: Number of Patients With a Decrease in Median Tumor SUV — 6 Participants
Brain Neoplasms
Primary: Objective Response Rates. Assessed With Cranial MRI — 78.6; 48.1 Percentage of participants with OR — p=0.019
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Glioblastoma Multiforme · Gliosarcoma
Primary: Overall Survival — 19 months